Catalyst Pharmaceuticals Stock News

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assertio (ASRT) delivered earnings and revenue surprises of -16.67% and 8.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

The FDA places a partial clinical hold on Alpine's (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck's Keytruda for treating advanced malignancies. Shares fall.

The Company Ranked 65th of More Than 1,000 Companies Assessed The Company Ranked 65th of More Than 1,000 Companies Assessed

CORAL GABLES, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX ), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that the Company is named on Forbes 2022 "America''s Best Small Companies" in its recently published list. The Company was ranked 65th of more than 1,000 companies evaluated. "It is a distinguished honor to be recognized by Forbes as one of the country''s best small companies," said Patrick J. McEnany, Chairman and CEO of Catalyst. "Our strong operating and financial performance result from our exceptional commercial and strategic execution. Having acknowledgment of the value we are creating is very gratifying, and I would like to thank all of our employees who share a commitment to the rare disease patients we serve." Forbes 2022 America''s Best Small-Cap Companies annual list was …

Pacira's (PCRX) flagship product, Exparel, has been performing well since its launch. The company's efforts to expand the drug's label also holds promise.

The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET

The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET

Catalyst Pharmaceuticals, Chinook Therapeutics, Assertio Holdings and Sigilon Therapeutics have been highlighted in this Industry Outlook article.

The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET

Catalyst Pharmaceuticals <> said the U.S. Patent and Trademark Office will issue three patents related to its drug Firdapse, used to treat Lambert-Eaton myasthenic syndrome…

JAZZ's product revenues grow in the fourth quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.

Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.

Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue in March 2022